All In MedTech

Device Trial Radar · NCT02862262

A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients

Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,052

Actual

Start

Jul 2016

Primary completion

Nov 2016

Study completion Nov 14, 2016

Sponsor

Lead sponsor
Luminex Molecular DiagnosticsNot on our public-company list
Sponsor type
Industry
First posted
Aug 11, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A three-arm, multi-site clinical evaluation of the ARIES Bordetella Assay for the detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acids in prospectively collected, de-identified, left-over clinical specimens; banked, pre-selected clinical specimens; and contrived specimens.

Conditions

  • Bordetella Infections
  • Bordetella Pertussis Infection
  • Bordetella Parapertussis Infection

Interventions

  • ARIES Bordetella AssayDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Specificity and sensitivity of the ARIES Bordetella Assay in patients suspected of having respiratory infection attributable to B. pertussis or B. parapertussis.Time frame: 5 months

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Indiana University Health

    Indianapolis, Indiana

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.